Antonio Cubillo Gracián

Author

Also Known As

A. C. Gracian, A. Cubillo Gracian, A. Cubillo Gracián, A.C. Gracian, A.C. Gracián, Antonio Cubillo Gracian, Antonio Cubillo Gracián, Ying Cheng

Publications

3.8K

Citations

H-Index

Concepts

All Affiliations

Hospital Universitario HM Sanchinarro Hospital General Universitario Gregorio Marañón Istituto Oncologico Veneto Universidad San Pablo CEU Vall d'Hebron Hospital Universitari

About

Antonio Cubillo Gracián is an author at Hospital Universitario HM Sanchinarro specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	1.9K
2	Health Sciences	5	5	418
3	Hepatology	3	3	236
4	Gastroenterology	2	2	73
5	Biomedical Engineering	1	1	24

Antonio Cubillo Gracián

Publications

3.7K

Citations

H-Index

Page 1

	Year	Citations
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia Iván O. Rosas, Norbert Bräu, Michael R. Waters, New England Journal of Medicine	2021	1.1K
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, The Lancet UrologySurgical OncologyGastrointestinal OncologyMedicineBiliary Cancer	2023	891
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study Arvind Dasari, Sara Lonardi, Rocio García‐Carbonero, The Lancet OncologyGastrointestinal OncologyColorectal CancerPharmacotherapyCancer Treatment	2023	279
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis Masatoshi Kudo, Ana Matilla, Armando Santoro, Journal of Hepatology	2021	215
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100 Markus Moehler, Mikhail Dvorkin, Narikazu Boku, Journal of Clinical Oncology	2020	212
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study James J. Harding, Jia Fan, Do‐Youn Oh, The Lancet Oncology MedicineBiliary CancerPathologyPharmacotherapyCancer Treatment	2023	201
Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia Iván O. Rosas, Norbert Bräu, Michael R. Waters, Clinical StatusClinical Infectious DiseaseClinical TrialsTocilizumab Versus PlaceboInfectious Respiratory Disease	2020	132
Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. Thomas Yau, Vittorina Zagonel, Armando Santoro, Journal of Clinical Oncology PharmacotherapyDurable ResponsesPre-clinical PharmacologyOncologyClinical Trials	2020	110
Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status. Masatoshi Kudo, Ana Matilla, Armando Santoro, Journal of Clinical Oncology ImmunologyPathologyImmunotherapeuticsImmunotherapyObjective Response Rate	2019	98
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial Thomas Yau, Vittorina Zagonel, Armando Santoro, Journal of Clinical Oncology	2022	63

Page 1